-
Did you mean
- alpha calprotectin
-
STELLUX® 4400 Chemiluminescence Plate ReaderCatalog #: 85-STX4400
Sample Size(s): Other
-
Calprotectin Chemiluminescence ELISACatalog #: 80-CALPHU-CH01
Sensitivity: 7.9 ug/g
Range: 7.9 - 6,000 ug/g
Sample Types: Stool
Sample Size(s): 96 Wells
Detection: Chemiluminescence
Alpco Home Page
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.Supporting your work with life science and clinical testing productsVIEW ALL LIFE SCIENCE PRODUCTSVIEW ALL CLINICAL DIAGNOSTIC PRODUCTS
Clinical Research
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.ALPCO has been serving the needs of clinical researchers and clinical diagnostics labs for over 30 years, and we now offer a broad product menu of proprietary automated sample-to-answer platforms. We’re ...
AACC 2023
Skip the crowd and reserve your time for a demonstration or individual meeting with a member of our team.Stop by Booth #2547
Ask About Our Targeted Solutions for Your GI Testing.Customized solutions for your calprotectin testing needs.GI SOLUTIONSEnsure AccuracyNew! Calprotectin Immunoturbidimetric...
Fecal Calprotectin Testing from Extraction to Results – Simplify Complexity
Immunoturbidimetric Assay for Fecal CalprotectinExtraction to Results – Simplify ComplexityLeverage the power of our FDA-Cleared Immunoturbidimetric (IT) Assay for fecal calprotectin designed to integrate seamlessly with your existing clinical chemistry analyzer. Experience a method that is not only...
New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time By Up To 86%
Date: January 26, 2016
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13...
De-escalating Inflammatory Bowel Disease Therapies
Date: June 21, 2016
Author: Andrea Tarbet, Product Marketing Associate at ALPCO
Several therapies exist to help treat inflammatory bowel disease (IBD) and improve patient quality of life. However, a growing number of gastroenterologists and patients have been choosing to stop these therapies -...
New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®
We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...
ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
July 25, 2018
ALPCO will exhibit at the AACC’s 70th Annual Clinical Lab Expo July 31-August 2, 2018 in Chicago, IL. The company will promote a number of tools to help research and improve clinical outcomes as well as increase laboratory efficiency.
Among these tools are new and upcoming additi...
Now Available: 510(k) Cleared Fecal Calprotectin ELISA
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test.
The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the cha...
ALPCO’s Calprotectin Validation Assistance Program
Whether your clinical laboratory is transitioning over to the ALPCO Calprotectin Chemiluminescence ELISA from another calprotectin assay or starting to run the test in-house for the first time, validation is the most crucial step in the assay implementation process. We understand that validating a n...
Managing Calprotectin as a Send Out?
While sending out for calprotectin testing offers some cost and convenience advantages when volumes are very low, bringing the process in-house allows for the opportunity to control costs, turnaround time, and quality. Considering costs and potential revenue, the volume at which in-house calprotecti...
Enhance Your Lab’s Molecular GI Portfolio
Molecular GI testing for bacteria such as salmonella, vibrio, and E. coli, and viral pathogens including norovirus and rotavirus, is instrumental in the diagnosis and treatment of infection and dysbiosis. In addition, many gastrointestinal disorders often require protein biomarker tests to aid in ac...
GI Testing
Calprotectin Chemiluminescence ELISA (80-CALPHU-CH01)
The Calprotectin Chemiluminescence ELISA is an in vitro diagnostic chemiluminescent assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human sto...
ALPCO receives FDA 510(k) clearance for the Calprotectin Immunoturbidimetric Assay
SALEM, NH, June 15, 2023 - American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, today announced recent FDA 510(k) clearance of its Calprotectin Immunoturbidimetric Assay.
Differentiating IBD from IBS with Fecal Calprotectin Testing
In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment pat...
High Throughput Calprotectin Testing with ALPCO Immunoturbidimetric Assay
Maximize lab efficiency with ALPCO's calprotectin immunoturbidimetric assay. Leverage existing analyzers, ensure accurate results, and improve turnaround times.
Boost Profitability with In-House Calprotectin Testing from ALPCO
Test results from outside laboratories can sometimes take up to 5 days. Random access testing enables laboratories to offer affordable same-day results. On-site testing eliminates the shipping process and maintains remnant samples on-site.
Consolidate and Improve Calprotectin Testing on Clinical Chemistry Analyzers with ALPCO
For laboratories with a compatible clinical chemistry analyzer, upgrading to the calprotectin immunoturbidimetric assay can improve efficiency and generate additional capacity. Laboratories can potentially eliminate a CLIA system or simply create new capacity on that system by transferring calprotec...
ALPCO's Superior Calprotectin Assay: Maximize Efficiency & Accuracy
Reduce False Positives from 26% to 7%! An increase in clinical specificity, and a decrease in false positives, enables clinicians to better evaluate IBD/IBS patients. Clinicians can schedule follow-up colonoscopies for the patients that need it most and start IBS patients on the right treatment path...
AutoPlex Automated Multiplex Biomarker Analysis
ALPCO’s automated multiplex assay, AutoPlex GI Panel, provides sensitive and accurate measurement of up to 5 GI biomarkers in human stool samples. The panel combines the workflow advantages of multiplexing with the proven reliability of traditional chemiluminescence sandwich immunoassays to enable b...
ALPCO Announces the Commercial Launch of its FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay
Salem, NH, December 19, 2023 – American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) d...
Live Webinar: Optimizing IBD Management with Fecal Calprotectin - From Diagnosis to Monitoring
In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..
Targeted Solutions for Gastroenterology
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.